Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) report encouraging results from an early phase clinical trial that found an experimental intranasal vaccine triggered a broad immune response against multiple strains of H5N1 “bird flu.”
This article was originally published on MedicalXpress.com

